Proteins associated with the bacterial membrane can be recruited for application as 27 antigens for the development of vaccines. This preliminary study was directed towards 28 evaluating the antigenic properties of the Pseudomonas aeruginosa (PA01) pscC protein 29 which is a component of the Type III secretion system. Gene specific primers were 30 designed to isolate the pscC gene which was isolated, ligated onto the multiple cloning 31 site of vector pGS21(a), cloned and expressed in Escherichia coli (BL21). The molecular 32 weight of the expressed pscC protein was determined by SDS-PAGE (10% sodium 33 dodecyl sulphate-polyacrylamide gel electrophoresis) and was found to be around 57 34 KDa and purified by the size exclusion chromatography. Finally, the purified pscC 35 protein was injected subcutaneously into adult Sprague Dawley® rats with a range of 36 concentrations (50, 100 and 150 µg per rat) respectively. Recombinant pscC antigen 37 induced a specific humoral immune response against the antigen, which was validated 38 by Enzyme-linked immunosorbent assay (ELISA). The results concluded that anti-pscC 39 antibody was elicited in the animal model.
INTRODUCTION
Pseudomonas aeruginosa is a versatile Gram negative aerobic bacillus, found in a wide 49 range of environmental habitats. This opportunistic pathogen causes both acute and chronic 50 infections in patients with hospital-acquired pneumonia [1] . It has been classified as the 51 fourth leading cause of nosocomial infection and is associated with cystic fibrosis; burn 52 wound infection, and pneumonic septicaemia [2] [3] . Due to recurrent causes of nosocomial 53 infections Pseudomonas infections have become more complex and life-threatening 54 infection, as standard treatments are becoming ultimately ineffective. This organism exhibits 55 intense signs of antibiotic resistance to a wide variety of antimicrobial treatments, including 56 Beta-lactams, Chloramphenicol and Fluoroquinolone [4] . Therefore, specific immune therapy 57 is more desirable than conventional antibiotic therapy [5] . 58 It is an urgent demand of time to implement therapeutic vaccination schemes against 59 Pseudomonas infections. P. aeruginosa have its own type III secretion system (T3SS), with a 60 protein translocation apparatus and the effector proteins which can be injected into host cells. 61 The secretion and translocation stages comprise over 20 proteins gathered into a needle-like 62 structure termed as injectisome [6] . The T3SS is the part of important virulence determinants 63 of P. aeruginosa, in which the pscC protein is a fundamental part of the needle tip for P. 64 aeruginosa (Fig 1) . The pscC protein has been established to be an important protective extension of 10 min at 72°C, the sample was cool to 4°C. The presence and yield of specific 126 PCR products of approximately 1,500 base-pair was confirmed by gel electrophoresis in 1% 127 agarose gel. DNA samples were loaded in wells and the electrophoresis was carried out at 128 100 volts. Then the DNA bands were visualized under ultraviolet (UV) trans-illuminator. by CaCl 2 method [16] . The insert plasmids were identified by colony PCR. The inserted 140 sequence and its reading frame were confirmed by EcoRI and HindIII digestion and DNA 141 sequence analysis. The generated pGS-pscC inserted plasmid was again sub-cloned into 142 competent expression cells of E. coli BL21 (DE3) following same method described as 143 cloned of Top10 competent cells.
144
The transformant cells were inoculated into the LB containing ampicillin in test tubes 
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The soluble fraction of pscC protein was purified by using by Size exclusion chromatography 162 (SEC). The SEC system (Akta Prime) was calibrated according to the supplier's instruction. PCR amplified product was run on a 1% agarose gel and desired band for the respective 215 target pscC gene was found without any primer and dimer. The PCR fragments were found to 216 be approximately 1.46 kb (Figure 2A ) amplified from the genomic DNA.
217
After confirmation, the PCR products were excised out of the agarose gel and purified 218 using a gel extraction kit and digested with restricted enzyme for conformation which was 219 represented in Figure 2B . The synthesized PCR product was then ready for cloning into pGS- and mass match were statistically more significant. Protein was analysed and noticed the one 258 matched peptide to the same pscC protein, which was higher confidence for correct protein 259 identified in Figure 6 . 
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The crude fraction was further purified and subjected to gel filtration on a Superdex followed 262 by purification analysis using SDS-PAGE. The chromatogram showed a mixture of monomer 263 and dimer state. The distinct peak was observed in 40 to 47 fractions and the small picks were 264 noticed in 22 to 41 fractions. Additional stage was precipitating the fractions followed by the to with the controls group. The control groups were always (Group-1) negative to the pscC 284 antigen throughout the study. The humoral immune responses were detected in all plasmid 285 immunized groups and continued increasing after 4th weeks of immunization as indicated by 286 the antibody level. The increased antibody was dose dependant until the 5th weeks. It was 287 noted that the medium dose (100 µg) and higher dose (150 µg) of protein antigen elicited a 288 stronger immune response as compared to the lower dose (50µg).
289
Pseudomonas aeruginosa is a major cause of most opportunistic and nosocomial 290 infections. Although conventional antibiotics are more resistance to Pseudomonas organism, 291 now it is challenging to find an alternative immunize therapy. In these circumstances, a 292 monoclonal antibody-based approach is still exploration for the inhibition of Pseudomonas 
303
It is supported that the use of genetic immunization technique in which a random assortment 304 of genes from a bacteria's genome to practice for immunization purposes [27] . So, it is 305 supposed to be clear that immunization is the best way of protection against outer membrane 306 secretin antigen of T3SS. outer membrane of oprF gene of P. aeruginosa was immunized by plasmid that indicated that 319 the efficacy of this vaccine can be able to elicited anti-oprF that confers protection of rodents 320 against chronic pulmonary infection. Moreover, the results are similar to previous published 321 14 results producing defence mechanism in rodent models by immunization with purified outer 322 membrane protein from P. aeruginosa [31] .
323
The fact is, without testing its effectiveness in animal models, the recombinant 324 antigen has not yet been applied to induce in the human body for assessment of their efficacy which is able to induce protection from Pseudomonas infection, might be more realistic for 334 ending global.
335
In précis, it is an appropriate challenging strategy for exploration of surface T3SS 336 pscC antigen, which has been characterized from P. aeruginosa PAO1 genome as a vaccine 337 candidate. The pscC gene (1.46 kb) encodes a 57-kDa immunogenic outer membrane 338 associated protein of P. aeruginosa PA01 strain. The protein was characterized in SDS-339 PAGE and purified from E. coli as a fusion protein to identify anti-pscC specific antibodies in 340 the serum of Sparagury rat. Therefore, it is posited that recombinant pscC protein is capable 341 of becoming a strong carrier and processor for the presentation of target foreign peptides in 342 MHC II to stimulate the T helper cell based humoral immune system in a host cell. The 343 expectations for treatment and prevention of human disease by immunization are changing, 344 and the recurrent refinement of these abilities signify a fit for the current as well as the future 345 manufacture of a vaccine platform against Pseudomonas infection. 
